Jun-Li Bao1, Yu-Bo Han2, Ke Zhang1, Li Liu2. 1. Heilongjiang University of Chinese Medicine, No.24, Heping Road, Xiangfang District, Haerbin. 2. Fist Affiliated Hospital, Heilongjiang University of Chinese Medicine, Haerbin, Heilongjiang, China.
Abstract
BACKGROUND: Pediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS. METHODS: Data in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature. RESULTS: The efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time. CONCLUSIONS: This study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS. PROSPERO REGISTRATION NUMBER: CRD42020146940.
BACKGROUND:Pediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS. METHODS: Data in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature. RESULTS: The efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time. CONCLUSIONS: This study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS. PROSPERO REGISTRATION NUMBER: CRD42020146940.
Authors: Amal Isaiah; Adam J Spanier; Lynn M Grattan; Yan Wang; Kevin D Pereira Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-10-01 Impact factor: 6.223
Authors: Armando Castorena-Maldonado; Laura Espinosa-Morett; Fernando Arredondo Del Bosque; José Luis Carrillo-Alduenda; Luis Torre-Bouscoulet; Juan Carlos Vázquez-García; José Rogelio Pérez-Padilla Journal: Rev Invest Clin Date: 2015 Jul-Aug Impact factor: 1.451
Authors: Alison Booth; Alex S Mitchell; Andrew Mott; Sophie James; Sarah Cockayne; Samantha Gascoyne; Catriona McDaid Journal: F1000Res Date: 2020-07-27
Authors: Azita Chehri; Serge Brand; Nastaran Goldaste; Sodabeh Eskandari; Annette Brühl; Dena Sadeghi Bahmani; Habibolah Khazaie Journal: Int J Environ Res Public Health Date: 2020-09-28 Impact factor: 3.390